세계의 조직공학 시장 보고서 : 유형, 용도, 최종 사용자 및 지역별(2024-2032년)

The global tissue engineering market size reached US$ 18.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 48.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032.

Tissue engineering (TE) is a biomedical engineering discipline that combines cells, scaffolds, and biologically active molecules into functional tissues. It applies the principles of life sciences and engineering to develop biological substitutes to restore, improve, maintain, or replace different types of tissues or organs. It provides efficient alternatives to transplants, surgical reconstruction procedures, and other mechanical devices that are used to repair damaged tissues. As a result, tissue engineering is rapidly gaining traction in numerous medical applications, including burn treatment, neurology, wound care, orthopedic, musculoskeletal, cardiovascular, and urological products. Nowadays, researchers are focusing on developing biomaterials for skin substitution to meet the growing demand for relatively cheaper and easily available skin replacement products.

Tissue Engineering Market Trends:

Tissue engineering procedures have proven effective in treating irreversible damage to tissues. This has led to a significant increase in the demand for regenerative medicines and TE procedures, which represents the primary factor driving the market growth. Besides this, the rising incidences of fatal road accidents and trauma injuries, along with the growing need for bone implants among patients, are augmenting the product demand. Additionally, the widespread prevalence of chronic diseases, such as diabetes, cancer, obesity and cardiovascular disorders, due to sedentary lifestyle habits, aging population and unhealthy diets, is catalyzing the market growth. Furthermore, technological advancements in the field of three-dimensional (3D) tissue engineering, such as organ-on-a-chip technology, replacement of embryo cells with stem cells, and use of 3D bioprinters to design in vitro implants efficiently, are offering lucrative opportunities to the market. Moreover, several product innovations, and the increasing government funding and private investments in research and development (R&D) activities are propelling the market growth. Other factors, including the growing number of replacements and reconstructive surgeries, rising consumer healthcare expenditure, and surging demand for plastic surgeries, are also creating a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global tissue engineering market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end user.

Breakup by Type:

Synthetic Scaffold Material

Biologically Derived Scaffold Material

Others

Breakup by Application:

Orthopedics and Musculoskeletal

Neurology

Cardiovascular

Skin and Integumentary

Dental

Others

Breakup by End User:

Hospitals and Clinics

Ambulatory Facilities

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.

Key Questions Answered in This Report

• 1. What was the size of the global tissue engineering market in 2023?
• 2. What is the expected growth rate of the global tissue engineering market during 2024-2032?
• 3. What are the key factors driving the global tissue engineering market?
• 4. What has been the impact of COVID-19 on the global tissue engineering market?
• 5. What is the breakup of the global tissue engineering market based on the type?
• 6. What is the breakup of the global tissue engineering market based on the application?
• 7. What are the key regions in the global tissue engineering market?
• 8. Who are the key players/companies in the global tissue engineering market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Tissue Engineering Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Synthetic Scaffold Material
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Biologically Derived Scaffold Material
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Orthopedics and Musculoskeletal
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Neurology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cardiovascular
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Skin and Integumentary
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Dental
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Facilities
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 B. Braun Melsungen AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Baxter International Inc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Becton, Dickinson and Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Integra LifeSciences Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Organogenesis Holdings Inc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 RTI Surgical
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Smith & Nephew plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Stryker Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Vericel Corporation
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Zimmer Biomet
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis